Skip to main content
. 2015 Oct 15;7(10):1782–1797.

Figure 5.

Figure 5

IL-22 secreted by ESCs promotes angiogenesis of VECs. (A, B) HUVECs were treated with rhIL-22 (100 ng/ml) or the supernatant from ESCs (n=6) pre-treated with or without α-IL-22 (5 ug/ml), with recombinant human VEGF (rhVEGF, 10 ng/ml) as positive control. Then tube formation assay was performed to analyze the angiogenesis of HUVECs. In addition, HUVECs were treated as described in Figure 4, and then the expression of CXCR1 and CXCR2 was detected by FCM (C-E). The data are expressed as the mean ± SEM. **P<0.01 and ***P<0.001 (one-way ANOVA). NS: no statistically difference.